Type 2 diabetes mellitus
Conditions
Interventions
From the start to the end of the study patients are treated with liraglutide every day.
From the start to the end of the study patients are treated with dulaglutide every week.
Sponsors
Haga Diabetes Clinic
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Type 2 diabetes mellitus patients. As for the study of diabetes control, patients with HbA1c higher than or equal to 6.5 % and lower than 10 %. As for the study of renal impairment, patients with eGFR<60mL/min/1.73m2, urine albumin >= 30mg/gCr, or urine protein >= 0.15g/gCr. As for the study of cognitive function, patients 70 years of age and older. Patients not planned to be treated with prohibited combined drugs
Exclusion criteria
Exclusion criteria: Type 1 diabetic patients. Patients with a history of severe ketosis or diabetic coma in previous 6 months. Patients with severe infection, before/after surgery or severe traumatic injury. Patients to have a plan to be pregnant. Patients with severe gastroenteric disturbance as exemplified by severe gastro-paresis. Patients with a history of pancreatitis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of HbA1c,body weight at the 52th and the 104th week. As for patients with renal disturbance, change of serum creatinine, urine albumin(mg/gCr), urine protein (g/gCr) at the 52th and the 104th week. As for patients over 70 years old, change of MMSE at the 52th and the 104th week. | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of data shown below at the 52th and the 104th week. AST, ALT, gamma-GTP, LDL-C, HDL-C,TG, non-HOL-C, serum creatinine, serum UA, eGFR, 1,5-AG, self-monitoring blood glucose, Urine albumin(mg/gCr),Urine protein (g/gCr) | — |
Countries
Japan
Contacts
Public ContactTatsuya Haga
Haga Diabetes Clinic Internal Medicine
Outcome results
None listed